In a randomized, controlled, double-blind study, researchers found that giving patients dexmedetomidine during cardiac surgery significantly improved their outcomes.

Here’s what they discovered:

Better Circulation: Patients who received dexmedetomidine had better microcirculation—the blood flow in their smallest vessels—after surgery. Specifically, their proportion of perfused vessels (PPV) and perfused vessel density (PVD) were higher. For instance, at 48 hours post-operation, their PVD was significantly higher than that of the control group (17.0 vs. 15.6 mm/mm²).

Healthier Kidneys: The dexmedetomidine group had a much lower rate of acute kidney injury (AKI), with only 11.8% of these patients developing the condition compared to 50% in the group that didn’t receive the drug.

Increased Urine Output: Patients receiving dexmedetomidine also produced significantly more urine during the operation (950 mL vs. 605 mL), which is a key indicator of good kidney function.

Overall, the study concluded that dexmedetomidine can help protect both microcirculation and kidney function in patients undergoing major cardiac procedures like valve replacement and aortic surgery.

Read More